Global, regional and national burden of alopecia areata and its associated diseases, 1990–2019: A systematic analysis of the Global Burden of Disease Study 2019

Abstract

Background No study to date has concomitantly reported the global burden of alopecia areata (AA) and its associated diseases. Methods The crude and age‐standardized rates of prevalence (ASPR), incidence (ASIR) and years lived with disability (YLDs) of AA were extracted from the global burden of disease, injuries and risk factors study (GBD) database between 1990 and 2019 for 204 countries and territories. We stratified the analysis by global region, nation, sex, age and sociodemographic index (SDI) to dissect the epidemiology of AA and its associated diseases. Results Alopecia areata was responsible for 0.024% of the total DALYs. Age‐standardized DALYs rate of AA was 7.51 [4.73–11.14] per 100,000. Overall ASPR, ASIR and age‐standardized YLDs rates were stable from 1990 to 2019 globally. All three rates were about two times higher in females compared to males and had a bimodal distribution with peaks at age 30–34 years and 60–64 years. AA burden was positively correlated with SDI (r = .375, p < .001) and was most prevalent in high‐income countries, especially North America. Countries with a high AA incidence were more likely to have high incidences of autoimmune diseases and low incidences of ischaemic heart disease and ischaemic stroke. Conclusions The burden of AA was prominent in females, young adults, high sociodemographic countries and North Americans. The study corroborates sex‐ and region‐specific implications and public health measures for AA and its associated burdens. These epidemiological data on AA burden can guide future research efforts, prevention strategies and allocation of resources.

To evaluate the role of interleukin-6 in alopecia areata

“…1 According to the global burden of disease (GBD) database 1990-2019, the age-standardised disability adjusted life years (DALYs) rate of AA was 7.51 (4.73-11.14) per 100,000 persons globally. 2 AA often manifests as an abrupt loss of hair in clearly defined areas. The affected region typically consists of a round-shaped patch of alopecia that may be widespread or localised.…”

Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra

“…Ischemic stroke is induced by sudden infarction of brain vessels, with a high rate of morbidity and mortality. − It is reported that ischemic stroke is the second highest cause of mortality worldwide, leading to 5.9 million deaths and 102 million disabilities. , Currently, the golden rule of clinical treatment for ischemic stroke is to restore blood reperfusion in the ischemic penumbra, ensuring that brain tissue can replenish blood oxygen and rescue damaged neurons, but survivors still are at high risk for disability, neurological deficits and other infections due to ischemia-reperfusion ending up with neuronal injury. , Therefore, there is an urgent need for the development of more feasible methods for ischemic stroke treatment.…”

Identification of Potential Therapeutic targets for Stroke and Its Subtypes by Integrating Proteomes and Genetics from Human Plasma

“…Stroke is the leading cause of death and long-term disability worldwide, which imposes a great burden on global health. 1 Despite significant advancements in the past decades, critical gaps persist in the management of stroke and its subtypes(i.e. large artery atherosclerosis, cardioembolic stroke, or small artery occlusion).…”